Ron Ron Cheng, MD
Urology · Albuquerque, NMNPI 1275828758
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,805 of the $2,768 with a category attached, or 65.2%. 6 manufacturers reported payments, led by Coloplast at 50.2% of the total. Reporting peaked in 2024 at $2,013 and has fallen 91.1% since, to $178 in 2025.
Across 16 payments — averaging $173.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Boston Scientific$935
- Axonics, Inc.$161
- Progenics Pharmaceuticals, Inc.$151
- Convatec Inc.$104
- Johnson & Johnson$28
What the payments were for
- Travel & lodging$1,80565%
- Food & beverage$96335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 7 | $1,390 |
| Boston Scientific | 5 | $935 |
| Axonics, Inc. | 1 | $161 |
| Progenics Pharmaceuticals, Inc. | 1 | $151 |
| Convatec Inc. | 1 | $104 |
| Johnson & Johnson | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIRTUE$987
- Lumenis Pulse 120H$784
- TITAN$364
- Bulkamid$161
- PYLARIFY$151
- GENERAL BPH$134
- GENTLECATH$104
How this compares
$2,768 in reported general payments places this provider in the 75th percentile of 46 urology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 39 | $33,231 |
| Tamsulosin Hcl | 73 | $1,036 |
| Solifenacin Succinate | 12 | $291 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $237 |
| Finasteride | 13 | $173 |
Paid to pharmacies, not to this prescriber.
Other urology in Albuquerque
- Wayne KuangAlbuquerque$128K
- Jordan ForemanAlbuquerque$60K
- Andrew GrollmanAlbuquerque$16K
- Aaron GeswaldoAlbuquerque$11K
- Jonathan NelsonAlbuquerque$6K
- Stefan GutowAlbuquerque$5K
- Frances AlbaAlbuquerque$3K
- Christopher SlaydenAlbuquerque$2K
- Frederick SnoyAlbuquerque$2K
- Damara KaplanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.